The effects of DL-tiprenolol (DU 2I445) -a new beta-receptor blocking agent -and atropine on both normal and abnormal conduction pathways in the Wolff-Parkinson-White (WPW) syndrome were studied by means of His bundle electrograms and atrial pacing. It was shown that DU 2I445 slows conduction through both pathways significantly (P, o os) and has a potential value in the treatment of symptomatic WPW syndrome and perhaps in other types of re-entrant tachycardias.
The effects of DL-tiprenolol (DU 2I445) -a new beta-receptor blocking agent -and atropine on both normal and abnormal conduction pathways in the Wolff-Parkinson-White (WPW) syndrome were studied by means of His bundle electrograms and atrial pacing. It was shown that DU 2I445 slows conduction through both pathways significantly (P, o os) and has a potential value in the treatment of symptomatic WPW syndrome and perhaps in other types of re-entrant tachycardias.
The effects of atropine were also studied in 2 patients. Atropine did not affect bypass conduction whereas A V conduction velocity was definitely increased.
The study also sheds further light on the mechanism of WPW syndrome. It was found that the bypass had different conducting properties and was most probably a different conducting structure from the normal A V pathway.
Surgical division of the anomalous pathway in the Wolff-Parkinson-White (WPW) syndrome has recently been carried out with some success in a few patients with incapacitating attacks of tachycardia (Cobb et al., I968; Sealy, Boineau, and Wallace, I970) . Attempts by others have been unsuccessful (Burchell et al., I967; Cole et al., I970; Lindsay et al., I97I) and in general the results of this surgical procedure have not, until recently, been particularly encouraging. Conventional medical treatment is therefore still the most widely used method of management, and most generally known antiarrhythmic drugs have, at one time or another, been proposed for the prevention and treatment of the arrhythmias associated with this syndrome.
The administration of beta-receptor blocking agents has been shown to be particularly effective in the prevention and treatment of the attacks of paroxysmal reciprocating tachycardias (Gianelly, Grifin, and Harrison, I967; Gibson and Sowton, I969). Nevertheless, failures with these agents have occurred in some of the most extensively studied series (Dreifus et control 'pace-run' was also studied. In Case 4 the effect of atropine was studied the day before the DU 21445 study.
DL-tiprenolol (DU 21445) is a new beta-blocking agent (Philips-Dulphar N.V. Weesp, The Netherlands) with about the same pharmacological actions as DL-propranolol, but three times more active in reducing heart rate during exercise (Kesteloot et al., I970) .
Statistical analysis of the data obtained with DU 21445 was executed on an IBM 360 computer. The values of the intervals at the pacing rates used for statistical analysis were derived from the basic data by linear interpolation on the scale of paced heart rates. The statistical test used was Wilcoxon's signed rank test for paired differences.
Subjects
There were 5 patients with WPW syndrome, who volunteered for the study after the procedure had been fully explained to them and their consent obtained. Definitions of intervals and terms PH and StH intervals These are the intervals measured from the beginning of the P wave (P) or from the stimulus artefact (St) to the rapid deflection of the His bundle spike on the intracardiac electrogram. They represent atrial depolarization plus AV nodal conduction. Since changes in atrial conduction time are minimal, changes in these intervals reflect almost exclusively changes in AV nodal conduction time.
Pd interval and Std interval These are the intervals measured from the beginning of the P wave (P) or from the stimulus artefact (St) to the beginning of the delta wave. These intervals represent atrial depolarization plus anomalous bypass conduction time. Since changes in atrial conduction time are minimal, changes in these intervals reflect almost exclusively changes in -bypass conduction time. Fig. 2 pre-excitation complexes prevail at rates of 147 to 194 beats a minute. Fig. 3 (Table i ). The QRS duration in Case 2, however, was somewhat longer after DU 21445, probably the result of some intraventricular conduction delay. In Case 4, DU 21445 was injected the day after the administration of the atropine. The intervals are depicted in Table i . Fig. 4 shows the results diagrammatically. Conduction through the bypass is i 5 msec longer after betablockade. Conduction through the normal AV pathway is also prolonged. The QRS duration lengthens with increasing heart rate and parallels the StH lengthening, but is also unaffected by the administration of DU 2I445. Table 2 shows the main statistical results of the 4 patients studied. Linear interpolation on the scale of paced heart rates was performed in order to obtain the values of the intervals at the rates used for statistical analysis. With respect to the effects of DU 21445 on the various intervals, significant differences from premedication values (P<o-o5) occurred with regard to: (a) the StH intervals at pacing rates of less than 8o beats a minute, (b) the Std intervals at rest or normal sinus rhythm, and at each pacing rate, and (c) the StS intervals at almost each pacing rate (Table 3) . Changes in resting and maximum pacing heart rates did not reach statistical significance, presumably due to the small sample.
2) Effects of atropine The effects following the administration of 2 mg atropine were studied in Cases 4 and 5 ( (Fig. 3) . The data are given in Table I (Fig. 6) control values recorded at the same heart rates. The His spike is always visible. The atropine results in enhanced AV conduction through the normal AV pathway thereby resulting in lesser degrees of pre-excitation fusion at pacing rates up to I67 beats a minute. There is no change in the Std interval or bypass conduction time. The QRS duration is shortened (when compared to the QRS duration at similar heart rates without atropine). This is due to the diminished contribution of the bypass impulse as a result of the faster AV conduction. The results are depicted diagrammatically in Fig. 7 .
Discussion
The prognosis of the WPW syndrome is usually considered to be benign (Berkman and Lamb, I968). Nevertheless, sudden and unexpected deaths have, on rare occasion, been reported (Dreifus et al., I97i) . Life insurance statistics also show a slightly increased mortality rate in WPW patients (Smith, I964) . The WPW syndrome could, therefore, be viewed as a potentially fatal condition, though this appears to be very rare indeed. However, morbidity secondary to intermittent tachycardias is considerable and treatment directed to the prevention and management of the complicating tachyarrhythmias is thus strongly indicated. The most attractive basis for the medical treatment of the supraventricular reciprocating tachycardias appears to be the prevention of re-entry by blocking one or both of the AV conducting pathways. The re-entry circuit in the majority of patients with the WPW syndrome, however, includes atrial tissue, the normal AV pathway, ventricular myocardium, together with bipolar atrial electrogram (BAE) and leads II and VI at increasing atrial pacing rates before the intravenous injection of 2 mg atropine. As the pacing rate is increased from 64 to I72 a minute the following effects occur: (i) the His spike (H) disappears in the QRS complex because of an increase in atrioventricular conduction time, (ii) the Std interval remains relatively (rather) constant, while (iii) the StS interval lengthens from 250 to 320 msec. A 'full-blown' pre-excitation complex is present at a rate of II7 beats a minute. (Chung, Walsh, and Massie, I965). Quinidine has been said to prevent impulse re-entry by increasing the refractory period of the atria and the ventricles (Blinder, Burstein, and Smelin, 1952) quinidine (Hoffman, Abernathy, and Haedicke, I952). Combination therapy with digitalis and quinidine has been used for the management of the re-entrant tachycardias; the rationale being that digitalis slows conduction through the AV node whereas quinidine prolongs atrial depolarization and depresses conduction within the bypass and the ventricles. These properties are combined in DL-propranolol. Indeed, electrophysiological studies by 'I. group.bmj.com on November 8, 2017 -Published by http://heart.bmj.com/ Downloaded from Effects of new beta-blocking agent (DL-tiprenolol) I28I Vaughan Williams (I966) and Davis and Temte (I968) have shown that DL-propranolol has a quinidine-like effect which results in slower myocardial conduction. This is represented by a reduction in the amplitude and rate of rise of the action potential and a prolongation of the effective refractory period.
Furthermore, DL-propranolol slows AV conduction by its beta-receptor blocking effect (Berkowitz et al., I969; Smithen, Balcon, and Sowton, I97I) .
Thus, DL-propranolol acts at the four sites of the re-entry pathway and should theoretically be an ideal drug in the management and prevention of the reciprocating tachycardias of the WPW syndrome. There is now ample evidence that beta-blocking agents are usually successful in the prevention and treatment of reciprocating tachycardias of the WPW syndrome (Gianelly et There was, however, an effect on bypass conduction which was consistently prolonged in the four patients whom we studied. This may possibly be due to muscle conduction being more affected than the Purkinje tissue.
In Cases i and 4, it was possible to induce and terminate the attacks of supraventricular tachycardia by properly timed atrial stimuli. After DL-tiprenolol, however, it was impossible to precipitate any tachycardias in Case i, and only short self-terminating attacks of tachycardia could be evoked in Case 4.
These always terminated with a 'retrograde' P wave which means that re-entry was blocked in the AV node and not in the bypass. Perhaps the drug can also be used with success in other types of re-entry tachycardias.
Atropine has been used for diagnostic purposes in order to diminish or, in some cases, abolish the pre-excitation fusion complex. This is due to an enhancement of normal AV conduction which thereby results in more complete normal activation. Blinder et al. (1952) reported that the effect of atropine on the bypass was negligible. This was also found in Cases 4 and 5 where the Std interval was unaffected by atropine. This study also sheds further light on the mechanism of the WPW syndrome. It indicates that the conduction properties of the normal AV nodal pathway and the anomalous pathway are different and unrelated and that the precise electrocardiographic manifestation is dependent upon an entirely unpredictable and at times fortuitous relation of these properties. This indicates not only differing physiological properties but also differing anatomical properties. The latter suggests too that the bypass is probably a different conducting structure.
